West Pharmaceutical Services (WST) Short term Debt (2009 - 2023)

West Pharmaceutical Services (WST) has reported Short term Debt for 15 consecutive years, with $2.2 million the latest figure, recorded in Q3 2023.

• Quarterly Short term Debt changed 0.0% year-over-year to $2.2 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $2.2 million (changed 0.0% YoY) and the FY2021 annual result came in at $44.2 million, up 1821.74% from the prior year.
• Short term Debt steadied at $2.2 million in Q3 2023 per WST's latest filing, from $2.2 million in the prior quarter.
• Over the last five years, Short term Debt for WST reached as high as $44.2 million in Q3 2021 and fell as low as $2.2 million in Q1 2022.
• A 5-year average of $7.8 million and a median of $2.3 million in 2019 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2019 — Short term Debt surged 2200.0% — and 2022, when it sank 95.02%.
• Year by year, Short term Debt stood at $2.3 million in 2019, then changed by 0.0% to $2.3 million in 2020, then surged by 1821.74% to $44.2 million in 2021, then plunged by 95.02% to $2.2 million in 2022, then changed by 0.0% to $2.2 million in 2023.
• According to Business Quant data, Short term Debt over the past three periods registered $2.2 million, $2.2 million, and $2.2 million for Q3 2023, Q2 2023, and Q1 2023 respectively.